BioCentury on BioBusiness,
Emerging Company Profile
ImmuSmol's antibodies target metabolites involved in tumor immune evasion
Related tables, figures and sidebars
ImmuSmol: Going small
Monday, March 31, 2014
Cancer cells can evade host immunity by up-regulating enzymes
that produce small molecule metabolites capable of blocking T cells in the
tumor microenvironment. ImmuSmol
S.A.S.'s antibodies target the metabolites to restore the immune
response to tumors while sidestepping problems associated with inhibiting the
Antibodies against small molecules were first developed in the
1940s, when researchers at the University
of Vienna discovered that conjugating a small molecule target to a
protein carrier could elicit antibodies against that target in vivo.
While such antibodies found use as immunohistochemical research tools, they
have not been widely harnessed therapeutically because of technical challenges
in constructing the appropriate target-carrier conjugates, ImmuSmol CEO Alban
Bessede told BioCentury.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]